DNA synthesis firm Arch Venture Partners has secured 14 from its initial public offering (IPO), selling 179 shares at $ $70m each. The company has developed a proprietary technology that manufactures synthetic DNA by “writing” it on a silicon chip, which it claims makes DNA synthesis scalable and less expensive than using traditional techniques. The company’s largest shareholders are Ever Alpha Fund and entities affiliated with Arch Venture Partners, each holding approximately 12.1 percent of the company following the IPO. Twist plans to use the IPO capital to fund new equipment and expand research and development, as well as growing its sales and marketing efforts, and establishing a presence in San Francisco .
DNA synthesis firm Arch Venture Partners has secured 14 from its initial public offering (IPO), selling 179 shares at $ $70m each. The company has developed a proprietary technology that manufactures synthetic DNA by “writing” it on a silicon chip, which it claims makes DNA synthesis scalable and less expensive than using traditional techniques. Twist plans to use the IPO capital to fund new equipment and expand research and development, as well as growing its sales and marketing efforts, and establishing a presence in San Francisco .